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ABSTRACT 
Glucosamine sulfate is a natural constituent of 
cartilage and is used in the treatment of knee 
osteoarthritis. The aim of this study is to pro-
vide a short but comprehensive pharmaco-
therapeutic update on treating knee osteoarthri-
tis with glucosamine sulfate. A literature search 
was conducted of PubMed, Centre for Reviews 
and Dissemination databases, Cochrane Re-
views and EconLit up to January 2010. The lit-
erature review indicated that the mechanism of 
action of glucosamine sulfate is based on hy-
pothesis, but its treatment effects in knee os-
teoarthritis are symptomatic. With steady-state 
peak concentrations at the 1,500 mg dosage in 
the range of 10 µM, it is estimated that only 2% 
of glucosamine is incorporated in the cartilage. 
A once-daily dosage of 1,500 mg of glucosa-
mine sulfate is licensed for the treatment of 
symptomatic osteoarthritis and has been shown 
to reduce pain, improve function and exhibit 
similar safety to placebo. Glucosamine sulfate 
is likely to be a cost-effective treatment of knee 
osteoarthritis. In conclusion, a once-daily dos-
age of 1,500 mg of glucosamine sulfate is likely 
to be a safe, effective and cost-effective treat-
ment of knee osteoarthritis as compared to 
placebo. 
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1. INTRODUCTION 
Knee osteoarthritis is associated with significant mor-
bidity, impaired quality of life, and substantial healthcare 
costs [1]. Pharmacological treatment of knee osteoarthri-
tis includes analgesics, non-steroidal anti-inflammatory 
drugs (NSAIDs), corticosteroids and opiods, and gluco-
samine sulfate. Glucosamine sulfate is a natural subs- 
tance that is a constituent of cartilage. Glucosamine sul-
fate is sold as a dietary supplement in the United States, 
but is registered as a medicine throughout much of 
Europe.  
To date, there is uncertainty over various pharmaco-
therapeutic aspects of treating knee osteoarthritis with 
glucosamine sulfate. Therefore, the aim of this study is 
to provide a short but comprehensive pharmacothera-
peutic update on treating knee osteoarthritis with gluco-
samine sulfate. 
2. METHOD 
2.1. Search Strategy 
A literature search was conducted of PubMed, Centre for 
Reviews and Dissemination databases, Cochrane Data-
base of Systematic Reviews and EconLit up to January 
2010. Additionally, the bibliography of included studies 
was checked for other relevant studies. Search terms 
included “knee osteoarthritis”, “knee joint”, “glucosa-
mine sulfate”, “pharmacokinetics”, “bioavailability”, “in-
dications”, “dosage”, “safety”, “effectiveness”, “cost- 
effectiveness”, “economic evaluation” alone and in com-
bination with each other.  
The literature search included articles published in 
peer-reviewed journals and congress abstracts. Also, the 
researchers contacted manufacturers of glucosamine 
sulfate for any unpublished studies. The review was lim-
ited to studies published in English for practical reasons. 
2.2. Inclusion and Exclusion Criteria 
The review was limited to the use of glucosamine sulfate 
in its indication of knee osteoarthritis. 
To explore the pharmacotherapy of glucosamine sul-
fate from a multidisciplinary perspective, the literature 
review assessed the following aspects: pharmacokinetics, 
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indications and dosage, safety and effectiveness, and 
cost-effectiveness. Evidence about cost-effectiveness was 
derived from economic evaluations. An economic evalua-
tion was defined as a study comparing glucosamine sul-
fate with an alternative treatment in terms of both costs 
and consequences.  
3. RESULTS 
3.1. Search Results 
The results of the literature search are displayed in Fig-
ure 1. The review summarized three studies on pharma-
cokinetics, a Cochrane literature review on safety and 
effectiveness, and three economic evaluations of gluco-
samine sulfate in knee osteoarthritis. 
3.2. Pharmacokinetics 
A literature review analysed the absorption, distribution, 
metabolism and excretion of different administration 
forms of glucosamine sulfate [2]. The absolute bioavail-
ability of oral glucosamine sulfate amounted to 44%. 
The fecal excretion was 11.3% of the dosage, indicating 
that at least 88.7% of the dosage was absorbed through 
the gastrointestinal tract. With an absolute bioavailability 
of 44% calculated after oral 14C-glucosamine, a first- 
pass effect can be hypothesized.  
A study examined the dosage-proportionality of glu-
cosamine sulfate in 12 healthy volunteers [3]. The phar-
macokinetics were linear in the 750 mg and 1,500 mg 
dosages, but not at 3,000 mg, where the plasma concen-
tration-time profiles were less than expected based on 
dosage-proportionality. More recent research showed 
that glucosamine concentrations in plasma and synovial 
fluid were correlated [4]. There remains controversy 
over whether steady-state peak concentrations at the 
1,500 mg dosage were in line with those found to be 
effective in selected in vitro studies. 
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Exclusion because of: 
- animal model of glucosamine sulfate 
- disease other than knee osteoarthritis 
- study not involving glucosamine 
sulfate 
- absence of data on pharmacokinetics, 
safety, effectiveness or 
cost-effectiveness 
- study measuring resource use (but 
not costs) 
7 articles included 
  
Figure 1. Flow chart of literature search. 
3.3. Indications and Dosage 
The indication of glucosamine sulfate in Europe is lim-
ited to the symptomatic treatment of knee osteoarthritis. 
An expansion of indication to osteoarthritis of the hip, 
spine, hands and other locations was refused, as a result 
of which some companies have refused to register their 
preparation as a medicine. Glucosamine sulfate can be 
used alone or in combination with NSAIDs. The li-
censed dosage is 1,500 mg, once daily. Symptom relief 
may not be experienced until after several weeks of 
treatment, and optimal effects on joint mobility have 
been observed after 12 weeks of administration. 
3.4. Safety and Effectiveness 
A Cochrane review assessed randomized controlled trials 
(RCTs) evaluating the effectiveness and toxicity of glu-
cosamine in osteoarthritis up to the end of 2008 [1]. Of 
the 25 studies included in the review, 20 RCTs focused 
on the knee exclusively and five RCTs examined os-
teoarthritis at other or multiple sites. All studies were 
double-blinded randomized parallel-group trials, enroll-
ing a total of 4,963 patients (mean age of 60.7 years, 
69% were female). Fourteen RCTs had affiliations with 
Rotta Pharmaceuticals (an Italian manufacturer of glu-
cosamine sulfate). 
A pooled analysis of the relevant RCTs showed that, 
as compared to baseline, glucosamine sulfate taken 
orally in amounts of 1,500 mg/day produced an increase 
in the total score of the Lequesne Index (a multidimen-
sional index measuring knee pain or discomfort, activi-
ties of daily living and maximum distance walked) of 
11% (standardized mean difference of –0.47; 95% con-
fidence interval: –0.82 to –0.12). A subgroup analysis of 
the Rotta preparation showed significant benefit over 
placebo in terms of pain (standardized mean difference 
of –1.11; 95% confidence interval: –1.66 to –0.57) and 
in terms of the total score of the Lequesne Index (stan-
dardized mean difference of –0.47; 95% confidence in-
terval: –0.82 to –0.12). Studies using a non-Rotta prepa-
ration failed to show benefit over placebo in terms of 
pain and function as measured by the Western Ontario 
and McMaster Universities Index (a disease-specific 
index measuring pain, stiffness and function). Two RCTs 
suggested that the Rotta preparation of glucosamine sul-
fate may slow radiological progression of knee os-
teoarthritis over a three-year period (average difference 
of 0.32; 95% confidence interval: 0.05 to 0.58).  
Glucosamine therapy exhibited a safety profile similar 
to placebo in terms of the number of patients with 
side-effects (relative risk ratio of 0.99; 95% confidence 
interval: 0.91 to 1.07) and significantly better than 
NSAIDs (relative risk ratio of 0.29; 95% confidence 
interval: 0.19 to 0.44). 
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3.5. Cost-Effectiveness 
A Belgian economic evaluation indicated that treatment 
of knee osteoarthritis with glucosamine sulfate for at 
least one year and up to three years was associated with 
a lower incidence of total knee replacement over an ob-
servation period of eight years [5]. Costs of glucosamine 
sulfate treatment were offset by lower hospitalization 
costs, resulting in overall savings. Total costs per patient 
amounted to € 1,103 in the placebo group and € 901 in 
the glucosamine sulfate group. In other words, treatment 
of knee osteoarthritis with glucosamine sulfate for up to 
three years is associated with savings of € 202 per pa-
tient during the overall observation period of eight years 
(i.e. up to three years of treatment and five years of fol-
low-up). This study indicated that glucosamine sulfate 
treatment was more effective and less expensive than 
placebo in knee osteoarthritis. If costs of other os-
teoarthritis medicines and other health care resource use 
are taken into account, the cost-effectiveness of gluco-
samine sulfate would even be more favourable. 
Openly accessible at  
The National Institute for Health and Clinical Excel-
lence in England and Wales compared the likely cost- 
effectiveness of selected treatments for knee osteoarthri-
tis [6]. This study did not provide a full economic 
evaluation, but presented UK healthcare costs alongside 
the effectiveness of each treatment option. The scope of 
costs was limited to treatment costs (such as medicine 
costs), but did not include other healthcare costs such as 
adverse event costs or decreased use of other medical 
resources. The results suggested that glucosamine sulfate 
(1,500 mg/day) is likely to be cost-effective as compared 
with placebo. 
A recent US analysis explored the cost-effectiveness 
of glucosamine sulfate treatment versus placebo in a 
hypothetical cohort of 100,000 patients who were 65 
years old and had knee osteoarthritis for five years [7]. A 
hybrid Markov-decision tree model was constructed us-
ing published effectiveness data and US fee schedules. 
Treatment with a daily dosage of 1,500 mg of glucosa-
mine sulfate turned out to be more effective and less 
expensive than placebo by delaying time to joint re-
placement surgery. However, cost-effectiveness results 
were sensitive to changes in several input parameters 
and the authors recommended additional research to 
inform decision making. 
4. CONCLUSIONS 
This study provided a pharmacotherapeutic update on 
treating knee osteoarthritis with glucosamine sulfate. 
Additionally, an economic evaluation explored the cost- 
effectiveness of treating knee osteoarthritis with gluco-
samine sulfate in Belgium. The main messages can be 
summarized as follows. The mechanism of action of 
glucosamine sulfate is based on hypothesis, but its 
treatment effects in knee osteoarthritis are symptomatic. 
A once-daily dosage of 1,500 mg of glucosamine sulfate 
has been licensed for the symptomatic treatment of knee 
osteoarthritis. Glucosamine sulfate has been shown to 
reduce pain and improve function of patients with knee 
osteoarthritis. Glucosamine sulfate therapy exhibits a 
safety profile similar to placebo and significantly better 
than NSAIDs. Finally, glucosamine sulfate is likely to be 
a cost-effective treatment of knee osteoarthritis. 
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